课题基金 / 基金详情

Vaccine Studies in HIV-infected Subjects

Vaccine Studies in HIV-infected Subjects
HIV 感染者的疫苗研究
批准号：
8148436
负责人：
Barney Graham
金额：
$55.53万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8148436
关键词：
DNAEducational MaterialsEligibility DeterminationEnrollmentGoalsHIV-1Immune responseIndividualInfectionMedication ManagementPhaseRecruitment ActivityScreening ResultTherapeuticTherapeutic StudiesVaccines

项目摘要

项目成果

Barney Graham的其他基金

相似基金

相关文献

中文摘要
翻译
VRC 100旨在招募和筛选HIV感染受试者，以获得治疗性HIV疫苗，以及开发用于HIV感染个体的其他疫苗。该筛选研究的结果用于确定受试者是否符合参与疫苗研究的资格要求。在入组疫苗研究之前，与受试者一起审查疫苗教育材料并提供给受试者。 VRC 101是VRC开发的两种候选HIV-1疫苗的第一个I期治疗研究，并以初免-加强方案给药。
英文摘要
VRC 100 was designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study were used to determine if the subject met eligibility requirements for participation a vaccine study. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into a vaccine study. VRC 101 was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular Immune Responses to RSV infection in Mice
Rapid Development of Vaccines for Emerging Viruses
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
海外基金